Our overall objective is the evaluation of existing and newly developed monoclonal antibodies as potential tumor markers of exfoliated bladder epithelial cells, and to identify those markers of potential clinical value in detection of bladder tumors, predicting their behavior and response to therapy.
The specific aims fall within three categories: 1) to rigorously test the sensitivity and specificity of binding to bladder tumor cells by a panel of 32 well characterized and presently available monoclonal antibodies to cell surface tumor-associated antigens, blood group related antigens, cytostructural antigens, oncogene- coded products, and growth factor receptors, (a) by immunohistochemistry on tissue sections of human bladder tumors, reactive or metaplastic urothelium in inflammatory processes and normal urothelium, (b) by immunocytochemistry on cytology smears of exfoliated bladder epithelial cells from patients with bladder tumors, cystitis and normal mucosa, (c) flow cytometry of bladder irrigation specimens and cell suspensions from resected tumors using dual parameter DNA/monoclonal antibody binding measurements and three parameter-dual laser DNA/double monoclonal antibody binding, 2) to correlate the antigenic phenotype of bladder tumors analyzed with (a) conventional histopathologic and cytologic features and flow cytometry parameters, (b) clinical course including tumor progression, metastases, and response to therapy, and 3) to establish a new subclassification of human bladder tumors based on immunophenotypic features reliable and useful in clinical management and prognosis. Our evaluation will involve comparative analysis of the cytology of exfoliated bladder epithelial cells, histology of resected tumors, flow cytometry of cell suspensions and bladder irrigation specimens, cystoscopy and biopsy findings; and a sequential evaluation of all the parameters mentioned above during follow- up of patients treated conservatively. These multiparameter analyses of human bladder tumors are expected to yield new markers for immunodiagnosis and important information about cellular differentiation and transformation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA047538-03
Application #
3191236
Study Section
Special Emphasis Panel (SRC (52))
Project Start
1988-04-10
Project End
1992-03-31
Budget Start
1990-04-01
Budget End
1992-03-31
Support Year
3
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Memorial Hospital for Cancer & Allied Di
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10021
Rabbani, Farhang; Koppie, Theresa M; Charytonowicz, Elizabeth et al. (2007) Prognostic significance of p27Kip1 expression in bladder cancer. BJU Int 100:259-63
Orlow, I; Cordon-Cardo, C (2002) Evaluation of alterations in the tumor suppressor genes INK4A and INK4B in human bladder tumors. Methods Mol Biol 179:43-59
Juan, Gloria; Hernando, Eva; Cordon-Cardo, Carlos (2002) Separation of live cells in different phases of the cell cycle for gene expression analysis. Cytometry 49:170-5
Sanchez-Carbayo, Marta; Socci, Nicholas D; Charytonowicz, Elizabeth et al. (2002) Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 62:6973-80
Hernando, E; Orlow, I; Liberal, V et al. (2001) Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer. Int J Cancer 95:223-7
Juan, G; Cordon-Cardo, C (2001) Intranuclear compartmentalization of cyclin E during the cell cycle: disruption of the nucleoplasm-nucleolar shuttling of cyclin E in bladder cancer. Cancer Res 61:1220-6
Albert, P S; McShane, L M; Shih, J H et al. (2001) Latent class modeling approaches for assessing diagnostic error without a gold standard: with applications to p53 immunohistochemical assays in bladder tumors. Biometrics 57:610-9
McShane, L M; Aamodt, R; Cordon-Cardo, C et al. (2000) Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res 6:1854-64
Szijan, I; Orlow, I; Dalamon, V et al. (2000) Alterations in the retinoblastoma pathway of cell cycle control in parathyroid tumors. Oncol Rep 7:421-5
Orjuela, M; Castaneda, V P; Ridaura, C et al. (2000) Presence of human papilloma virus in tumor tissue from children with retinoblastoma: an alternative mechanism for tumor development. Clin Cancer Res 6:4010-6

Showing the most recent 10 out of 72 publications